Biomedical Engineering Reference
In-Depth Information
Table 7.2 Clinical Status of AS ODN Formulations
S. No.
Developer/
Partner
Reference
Product
Details
Clinical
Status as on
Dec. 2009
Drug Target
Indication
Route of
Delivery
Delivery System
1.
AVI Biopharma,
Inc.
http:// www
.avibio.com/
AVI-4658
Phase Ib/II
Exon 51
Duchenne muscular
dystrophy
Intramuscular
Morpholino-
oligomer
2.
Neopharm
http:// www
.neopharm.com/
LErafAON-
ETU
Phase I
Raf-1 protein
Neoplasms
Intravascular
infusion
Liposomes
3.
ISIS/Novartis
http:// www
.isispharm.com/
Vitravene
(Fomivirsen)
Marketed
CMV IE
CMV retinitis
Ocular
PS
ISIS/OncoGeneX
OGX-427
OGX-011
Phase I
Phase II
Hsp 27
Clusterin
Bladder cancer
Cancer
Intravesical
instillation
MBO
MBO
Isis/Genzyme
Mipomersen
Phase III
apoB-100
Cardiovascular
Subcutaneous
injection
AS ODN drug
Isis/Bristol Myers
Squibb
BMS-
PCSK9 Rx
Preclinical
PCSK9
Cardiovascular
Not available
AS ODN drug
Isis/Alsa, MDA
ISIS-SOD1 Rx
Preclinical
superoxide
dismutase, or
SOD1
Amyotrophic lateral
sclerosis
Not available
AS ODN drug
Isis/antisense
ACHN-490
Preclinical
growth hormone
receptor, or GHr
Acromegaly
Not available
AS ODN drug
Isis/Excaliard
EXC001
Phase I
Antifibrotic
Not available
AS ODN drug
ISIS/Teva
ATL/TV1102
Phase II
CD49d
Multiple sclerosis
Not available
MOE
ISIS/iCo
Therapeutics Inc/
ISIS
iCo-007
Phase I
c-Raf
Diabetic retinopathy Not available
Phosphothiorate
AS ODN
Isis
Pharmaceuticals
ISIS 104838
Phase II
TNF-alpha
messenger RNA
Rheumatoid arthritis Subcutaneous
injection
Phosphothiorate AS
ODN
( Continued )
 
Search WWH ::




Custom Search